anthracene

1.	Yoshida, Hiroki: 4 articles (03/2008 - 01/2006)
2.	Umekita, Yoshihisa: 4 articles (03/2008 - 01/2006)
3.	Kawaguchi, Hiroaki: 3 articles (03/2008 - 01/2006)
4.	Souda, Masakazu: 3 articles (03/2008 - 01/2006)
5.	Funato, Mamoru: 3 articles (01/2007 - 01/2006)
6.	Takasuka, Nobuo: 3 articles (05/2004 - 07/2002)
7.	Tsuda, Hiroyuki: 3 articles (05/2004 - 07/2002)
8.	Fukamachi, Katsumi: 3 articles (05/2004 - 07/2002)
9.	Han, Beom Seok: 3 articles (05/2004 - 07/2002)
10.	Gejima, Kentaro: 2 articles (03/2008 - 01/2006)

Related Diseases

1.	Neoplasms (Cancer) 01/01/1992 - "The application of EGCG before challenge with 7,12-dimethylbenz[a]anthracene as tumor initiator resulted in significant reduction both in percentage of mice with tumors and number of tumors per mouse compared with a non-EGCG-pretreated group of animals. " 07/01/2008 - "To assess the relative roles of Atm, Arf, and p53 in the suppression of Ras-driven tumors, we examined susceptibility to skin carcinogenesis in 7,12-dimethylbenz(a)anthracene/12-O-tetradecanoylphorbol-13-acetate (TPA)-treated Atm- and p53-deficient mice and compared these results to previous studies on Arf-deficient mice. " 06/23/2006 - "In vivo studies indicated that C3G treatment decreased the number of non-malignant and malignant skin tumors per mouse induced by 12-O-tetradecanolyphorbol-13-acetate (TPA) in 7,12-dimethylbenz[a]anthracene-initiated mouse skin. " 01/01/2004 - "Many toxicology studies on AQ used contaminated anthracene-derived AQ-OX, including a National Toxicology Program (NTP) 2-year cancer bioassay that reported a weak to modest increase in tumors in the kidney and bladder of male and female F344/N rats and in the livers of male and female B6C3F1 mice. " 02/20/2003 - "The question of whether cancer risk is influenced by time-of-day exposure to potentially carcinogenic agents was approached in this study by exposing mouse skin to a single initiating dose of 7,12-dimethylbenz [A-]anthracene, followed by a 12 week regime of bi-weekly skin treatments with the tumor promoter, 12-0-tetradecanoyl-phorbol acetate (TPA), given at four different circadian clock times (CCTs). " Order ALL the reference details at left...
2.	Carcinoma (Carcinomatosis) 01/01/1984 - "Parallel tumour induction studies showed that TPA increased markedly the incidence of tracheal carcinomas following initiation with a low dose of 7,12-dimethylbenz[a]anthracene. " 05/01/2006 - "[Effects of mobile-phone microwave on dimethylbenz (a) anthracene induced mammary carcinoma development in rats]" 01/01/2006 - "Effects of neonatally-administered 17beta-estradiol on induction of mammary carcinomas by 7, 12-dimethylbenz[a]anthracene in female rats." 11/28/2005 - "At day 0, all hamsters were challenged in the submucosa of the right cheek pouch with HER-2-positive HCPC I cells established in vitro from an 7,12-dimethylbenz[a]anthracene-induced oral carcinoma. " 02/01/2000 - "However, carcinomas developed rapidly in the T7-PKCepsilon mice treated with 7, 12-dimethylbenz[a]anthracene and TPA. " Order ALL the reference details at left...
3.	Breast Neoplasms (Breast Cancer) 12/05/2008 - "HL-37, a novel anthracene derivative, induces Ca(2+)-mediated apoptosis in human breast cancer cells." 07/01/2008 - "Induction of breast cancer was achieved by using the 7,12-dimethylbenz(a) anthracene. " 07/01/2006 - "Female Sprague Dawley rats at 55 days of age were treated with dimethylbenz(a)anthracene to induce breast cancer. " 11/01/2005 - "To identify high-frequency, low-penetrance breast cancer modifier genes, we have developed a rat genetic model that uses the Wistar-Kyoto (WKy) inbred strain, resistant to developing 7,12-dimethylbenz[a]anthracene-induced mammary carcinogenesis, as a congenic donor and the susceptible Wistar-Furth (WF) strain as the recipient. " 08/01/2002 - "Histopathologic characterization of mammary neoplastic lesions induced with 7,12 dimethylbenz(alpha)anthracene in the rat: a comparative analysis with human breast tumors." Order ALL the reference details at left...
4.	Papilloma (Papillomatosis) 01/01/1992 - "This study was designed to evaluate the point mutations in the murine c-Ha-ras gene of skin papillomas induced by initiation with dibenz[a,j]anthracene (DB[a,j]A), its bay-region anti-diol epoxide ((+/-)anti-DB[a,j]A-DE), and a 7,14-dimethyl analogue (7,14-diMeDB[a,j]A). " 02/01/2005 - "In addition, IH-901 given prior to each topical dose of TPA markedly lowered the number of papillomas in mouse skin induced by 7,12-dimethylbenz[a]anthracene. " 12/01/2001 - "Because 7,12-dimethylbenz[a]anthracene induces an activating mutation of H-ras, this provides one possible explanation for suppression of papilloma formation when FAK protein is limiting." 12/01/2001 - "We found that fak +/- heterozygous mice display reduced 7,12-dimethylbenz[a]anthracene-induced papilloma formation that correlates with reduced FAK protein expression in the skin. " 10/01/2000 - "Dimethylbenz[a]anthracene-initiated female ICR mice were treated with TPA (1.6 nmol) twice weekly for 20 weeks to promote papilloma formation. " Order ALL the reference details at left...
5.	Hyperplasia 06/01/2009 - "We next determined their effects on a 4 week inflammatory hyperplasia assay using 7,12-dimethylbenz[a]anthracene-induced murine skin carcinogenesis model to further understand their mechanism of action. " 07/15/1990 - "Concomitant with 7,12-dimethylbenz[a]anthracene-induced hyperplasia, there were some topographical alterations in the distribution of K14. " 01/01/1969 - "Epidermal hyperplasia induced by 7,12-dimethylbenz[a]anthracene in prosimians." 08/01/1982 - "Potentially neoplastic outgrowths of BALB/c mouse mammary hyperplasia(s) (MH) derived from 7,12-dimethylbenz[a]anthracene-transformed epithelial cells in organ culture were characterized for responses to the hormones normally required for morphogenesis and functional differentiation of the mammary tissue. " 01/01/1995 - "PGHS-1 steady-state levels remained unchanged upon induction of acute or chronic epidermal hyperplasia by TPA and in papillomas and carcinomas generated by the initiation-promotion procedure, with 7,12-dimethylbenz[a]anthracene as initiator and TPA as promoter. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	9,10-Dimethyl-1,2-benzanthracene (DMBA)
2.	Selenium
3.	Carcinogens
4.	Sodium Selenite (Selenite)
5.	Guanosine Triphosphate (GTP)
6.	sulforafan (sulforaphane)
7.	Methylcholanthrene
8.	mezerein
9.	Silymarin
10.	Methylnitrosourea (N-Methyl-N-nitrosourea)

Related Therapies and Procedures

1.	Chemoprevention
2.	Drug Therapy (Chemotherapy)
3.	Oral Administration
4.	Aftercare (After-Treatment)
5.	Transplantation (Transplant Recipients)

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>